Community Health Media

In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09.

They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) replace existing standards of care.

...

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.

From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-ma...

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making.

The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative disease. The panel also examines...

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure?

The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-month progression-free survival ...

Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates in early-stage HER2-positive breast cancer.

The discussion dives into DESTINY-Breast 11 and DESTINY-Breast 05, exploring how trastuzumab deruxtecan is challenging long-standing neoadjuvant and adjuvant paradigms. From pathologic complete response and invasive disease-free ...

For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control.

Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates.

The discussion explores the re...

Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the long-standing Cleopatra regimen is finally giving way to a new first-line standard in HER2-positive metastatic breast cancer.

From Destiny-Breast09 and unprecedented progression-free survival results to response depth, CNS considerations, and the real-world implications of...

For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer.

Now, DESTINY-Breast09 is forcing a fundamental rethink.

In this in-depth roundtable, Drs. Neil Iyengar, Komal Jhaveri, and Igor Makhlin examine:

• The legacy — and limitations — of CLEOPATRA

• DESTINY-Breast09’s unprecedented ~40-month PFS

• When T-DXd + pertuzumab should move to the frontline

• Patient selection, toxicity manageme...

Recorded at SABCS 2025, Dr. Neil Iyengar and Dr. Martin Dietrich break down the data that may finally dethrone CLEOPATRA as the long-standing first-line standard for HER2-positive metastatic breast cancer.

From the historic success of dual HER2 inhibition to the game-changing DESTINY-Breast09 results showing median PFS exceeding 40 months, this conversation explores what true progress looks like — and how it should change clinic...

Recorded live at ASCO 2025, Amy Krie, Mabel Mardones, and Anne O'Dea break down the data that could redefine first-line treatment for HER2-positive metastatic breast cancer.

From the legacy of CLEOPATRA to the stunning DB09 results showing median PFS exceeding 40 months, this expert roundtable explores what this shift means in real-world practice.

They tackle patient selection, CNS metastases, toxicity management, dose re...

Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.

This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications for brain metastases, response d...

In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.

They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in real-world practice.

From refr...

In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.

From DESTINY-Breast 09 to real-world decision-making, they discuss what a 40-month median PFS truly means, how T-DXd compares to THP, and whether “if it ain’t broke, don’t fix it” still applies.

They also tackle sequencing strateg...

Recorded live at ESMO 2025 in Berlin, this expert roundtable features Drs. Adam Brufsky, VK Gadi, Ian Krop, Neil Iyengar, Paolo Tarantino, Giancarlo Moscol, Shanu Modi, and Maryam Lustberg as they tackle the most pressing questions shaping breast cancer care today.

From HER2-low and ultra-low disease to antibody–drug conjugates, trial interpretation, sequencing strategies, and what truly defines “best first therapy,” this conver...

Triple-negative breast cancer has entered a new era.

At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.

Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.

#BreastCanc...

The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it.

In this deep-dive from ESMO 2025, Dr. Gregory Vidal and Dr. Erika Hamilton break down what the latest T-DXd data means for real-world practice, how ILD should be monitored, and why sequencing matters more than ever.

#BreastCancer #HER2 #HER2Low #TDXd #TrastuzumabDeruxtecan #ESMO2025 #DB05 #DB11 #OncologyEducation ...

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).

Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.

Drs. Pegram and Garrido-Castro explore:

• Why T...

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain?

In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS-active strategies, and how upco...

From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving.

In this episode, Dr. Neil Iyengar and Dr. Mark Robson explore how germline testing, risk stratification, and therapy sequencing are shaping adjuvant treatment decisions for BRCA1/2-mutated breast cancer.

They discuss:

🔹 Who should be tested — and how testing criteria are expanding.

🔹 Key takeaways from OlympiA and long-term data o...